FDA Allows Outsourcing Facilities to Extend Beyond-Use Date for Repackaged Avastin

February 2, 2018: By Joan McKenna

Avastin is repackaged into smaller doses for IVT use.

The US FDA will allow outsourcing facilities to extend the beyond-use date (BUD) for repackaged Avastin if additional sterility testing is undertaken, the agency announced Jan. 19.

The FDA released the policy change in two published final guidance documents on compounding.

In response, the American Society of Cataract and Refractive Surgery said it was working with the ophthalmic community to identify the cost and time associated with the test and the opinions of outsourcers on the final guidance.

The current BUD for repackaged Avastin is 90 to 180 days, according to a Minnesota retina specialist.

Draft guidance released in February 2015 called for a BUD of no more than five days for biologics repackaged at 503B outsourcing facilities. The clock would start once the package was opened at an outsourcing facility for repackaging.

Critics said the short timetable would make it impossible for Avastin to be repackaged, labeled, shipped, handled, and used by a surgeon, much less tested for sterility.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023